These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 29178616)

  • 1. Diffusion-weighted MRI characteristics associated with prognostic pathological factors and recurrence risk in invasive ER+/HER2- breast cancers.
    Amornsiripanitch N; Nguyen VT; Rahbar H; Hippe DS; Gadi VK; Rendi MH; Partridge SC
    J Magn Reson Imaging; 2018 Jul; 48(1):226-236. PubMed ID: 29178616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apparent diffusion coefficient in estrogen receptor-positive and lymph node-negative invasive breast cancers at 3.0T DW-MRI: A potential predictor for an oncotype Dx test recurrence score.
    Thakur SB; Durando M; Milans S; Cho GY; Gennaro L; Sutton EJ; Giri D; Morris EA
    J Magn Reson Imaging; 2018 Feb; 47(2):401-409. PubMed ID: 28640531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diffusion-weighted MRI of estrogen receptor-positive, HER2-negative, node-negative breast cancer: association between intratumoral heterogeneity and recurrence risk.
    Kim JY; Kim JJ; Hwangbo L; Lee JW; Lee NK; Nam KJ; Choo KS; Kang T; Park H; Son Y; Grimm R
    Eur Radiol; 2020 Jan; 30(1):66-76. PubMed ID: 31385051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of diffusion weighted imaging as supplement to dynamic contrast enhanced breast MRI: Can it help predict malignancy, histologic grade and recurrence?
    Roknsharifi S; Fishman MDC; Agarwal MD; Brook A; Kharbanda V; Dialani V
    Acad Radiol; 2019 Jul; 26(7):923-929. PubMed ID: 30293819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Convolutional Neural Network Using a Breast MRI Tumor Dataset Can Predict Oncotype Dx Recurrence Score.
    Ha R; Chang P; Mutasa S; Karcich J; Goodman S; Blum E; Kalinsky K; Liu MZ; Jambawalikar S
    J Magn Reson Imaging; 2019 Feb; 49(2):518-524. PubMed ID: 30129697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
    Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between Oncotype DX recurrence score and dynamic contrast-enhanced MRI features in patients with estrogen receptor-positive HER2-negative invasive breast cancer.
    Kim HJ; Choi WJ; Kim HH; Cha JH; Shin HJ; Chae EY
    Clin Imaging; 2021 Jul; 75():131-137. PubMed ID: 33548871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diffusion-weighted imaging (DWI) with apparent diffusion coefficient (ADC) mapping as a quantitative imaging biomarker for prediction of immunohistochemical receptor status, proliferation rate, and molecular subtypes of breast cancer.
    Horvat JV; Bernard-Davila B; Helbich TH; Zhang M; Morris EA; Thakur SB; Ochoa-Albiztegui RE; Leithner D; Marino MA; Baltzer PA; Clauser P; Kapetas P; Bago-Horvath Z; Pinker K
    J Magn Reson Imaging; 2019 Sep; 50(3):836-846. PubMed ID: 30811717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Support vector machine for breast cancer classification using diffusion-weighted MRI histogram features: Preliminary study.
    Vidić I; Egnell L; Jerome NP; Teruel JR; Sjøbakk TE; Østlie A; Fjøsne HE; Bathen TF; Goa PE
    J Magn Reson Imaging; 2018 May; 47(5):1205-1216. PubMed ID: 29044896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiparametric MR Imaging Radiomics Signatures for Assessing the Recurrence Risk of ER+/HER2- Breast Cancer Quantified With 21-Gene Recurrence Score.
    Chen Y; Tang W; Liu W; Li R; Wang Q; Shen X; Gong J; Gu Y; Peng W
    J Magn Reson Imaging; 2023 Aug; 58(2):444-453. PubMed ID: 36440706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score?
    Auerbach J; Kim M; Fineberg S
    Arch Pathol Lab Med; 2010 Nov; 134(11):1697-701. PubMed ID: 21043825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic contrast-enhanced and diffusion-weighted MRI of estrogen receptor-positive invasive breast cancers: Associations between quantitative MR parameters and Ki-67 proliferation status.
    Shin JK; Kim JY
    J Magn Reson Imaging; 2017 Jan; 45(1):94-102. PubMed ID: 27313102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL.
    Li W; Newitt DC; Wilmes LJ; Jones EF; Arasu V; Gibbs J; La Yun B; Li E; Partridge SC; Kornak J; ; Esserman LJ; Hylton NM
    J Magn Reson Imaging; 2019 Dec; 50(6):1742-1753. PubMed ID: 31026118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Test-retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trial.
    Newitt DC; Zhang Z; Gibbs JE; Partridge SC; Chenevert TL; Rosen MA; Bolan PJ; Marques HS; Aliu S; Li W; Cimino L; Joe BN; Umphrey H; Ojeda-Fournier H; Dogan B; Oh K; Abe H; Drukteinis J; Esserman LJ; Hylton NM;
    J Magn Reson Imaging; 2019 Jun; 49(6):1617-1628. PubMed ID: 30350329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Prognostic Significance of the Oncotype DX Recurrence Score in T
    Wang M; Wu K; Zhang P; Zhang M; Ding A; Chen H
    Ann Surg Oncol; 2019 May; 26(5):1227-1235. PubMed ID: 30456680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of dynamic contrast-enhanced MRI in evaluating the association between contralateral parenchymal enhancement and survival outcome in ER-positive, HER2-negative, node-negative invasive breast cancer.
    Shin GW; Zhang Y; Kim MJ; Su MY; Kim EK; Moon HJ; Yoon JH; Park VY
    J Magn Reson Imaging; 2018 Dec; 48(6):1678-1689. PubMed ID: 29734483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer.
    Nguyen TTA; Postlewait LM; Zhang C; Meisel JL; O'Regan R; Badve S; Kalinsky K; Li X
    Breast Cancer Res Treat; 2022 Apr; 192(3):509-516. PubMed ID: 35084624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
    Milburn M; Rosman M; Mylander C; Tafra L
    Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiparametric MRI model with dynamic contrast-enhanced and diffusion-weighted imaging enables breast cancer diagnosis with high accuracy.
    Zhang M; Horvat JV; Bernard-Davila B; Marino MA; Leithner D; Ochoa-Albiztegui RE; Helbich TH; Morris EA; Thakur S; Pinker K
    J Magn Reson Imaging; 2019 Mar; 49(3):864-874. PubMed ID: 30375702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiparametric diffusion-weighted imaging in breast lesions: Association with pathologic diagnosis and prognostic factors.
    Suo S; Cheng F; Cao M; Kang J; Wang M; Hua J; Hua X; Li L; Lu Q; Liu J; Xu J
    J Magn Reson Imaging; 2017 Sep; 46(3):740-750. PubMed ID: 28139036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.